{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:03:04Z","timestamp":1782205384097,"version":"3.54.5"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"1198","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Systemic sclerosis is a rare rheumatic disease characterized by immune cell activation, tissue fibrosis, and endothelial dysfunction. Extracellular matrix synthesis disorder causes widespread fibrosis, primarily in skin and internal organs. Various factors such as TGF\u03b2, VEGF, Galectin-3, and signaling pathways like Wnt\/\u03b2-catenin are involved in pathophysiological processes. Treatment lacks a unified approach but combines diverse modalities tailored to disease subtype and progression. Current therapeutic strategies include biologics, JAK inhibitors, and IL-6 pathway modulators. Monoclonal antibodies and hypomethylating agents demonstrate potential in fibrosis inhibition. This review focuses on emerging therapeutic evidence regarding drugs targeting collagen, cytokines, and cell surface molecules in systemic sclerosis, aiming to provide insight into potential innovative treatment strategies.<\/jats:p>","DOI":"10.1093\/postmj\/qgae169","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T15:05:06Z","timestamp":1733843106000},"page":"680-689","source":"Crossref","is-referenced-by-count":3,"title":["Fibrosis mechanisms in systemic sclerosis and new potential therapies"],"prefix":"10.1093","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1081-7928","authenticated-orcid":false,"given":"Raffaele","family":"Barile","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1356-8423","authenticated-orcid":false,"given":"Cinzia","family":"Rotondo","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9105","authenticated-orcid":false,"given":"Valeria","family":"Rella","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Trotta","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-9177","authenticated-orcid":false,"given":"Francesco Paolo","family":"Cantatore","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Medical and Surgical Sciences, University of Foggia , Luigi Pinto 1, 71121, Foggia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2025072207313261700_ref1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/ijms232012654","article-title":"Collagen V \u03b11 chain decrease in papillary dermis from early systemic sclerosis: a new proposal in cutaneous fibrosis molecular structure","volume":"23","author":"De Morais","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025072207313261700_ref2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s41927-022-00262-2","article-title":"Skin model for improving the reliability of the modified Rodnan skin score for systemic sclerosis","volume":"6","author":"Pongkulkiat","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2025072207313261700_ref3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11926-020-00970-z","article-title":"Skin histology in systemic sclerosis: a relevant clinical biomarker","volume":"23","author":"Showalter","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2025072207313261700_ref4","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1136\/annrheumdis-2018-214865","article-title":"Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease","volume":"78","author":"Valenzi","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jid.2022.08.052","article-title":"Reduced SPAG17 expression in systemic sclerosis triggers myofibroblast transition and drives fibrosis","volume":"143","author":"Sapao","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025072207313261700_ref6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41584-019-0324-5","article-title":"Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases","volume":"16","author":"Hinz","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025072207313261700_ref7","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/art.41192","article-title":"Promotion of myofibroblast differentiation and tissue fibrosis by the leukotriene B4\u2013leukotriene B4 receptor axis in systemic sclerosis","volume":"72","author":"Liang","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025072207313261700_ref8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","article-title":"Fibrosis: from mechanisms to medicines","volume":"587","author":"Henderson","year":"2020","journal-title":"Nature"},{"key":"2025072207313261700_ref9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/path.5680","article-title":"TGF-\u03b2 as a driver of fibrosis: physiological roles and therapeutic opportunities","volume":"254","author":"Budi","year":"2021","journal-title":"J Pathol"},{"key":"2025072207313261700_ref10","doi-asserted-by":"publisher","first-page":"10945","DOI":"10.1002\/jcb.28489","article-title":"Differential roles of VEGF: relevance to tissue fibrosis","volume":"120","author":"Zhang","year":"2019","journal-title":"J Cell Biochem"},{"key":"2025072207313261700_ref11","doi-asserted-by":"publisher","first-page":"650605","DOI":"10.3389\/fphar.2021.650605","article-title":"Circulating Galectin-1 and Galectin-3 in sera from patients with systemic sclerosis: associations with clinical features and treatment","volume":"12","author":"Sundblad","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025072207313261700_ref12","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/RHU.0000000000001367","article-title":"Galectin-1 and Galectin-3 expression in lesional skin of patients with systemic sclerosis\u2014association with disease severity","volume":"27","author":"Mora","journal-title":"JCR"},{"key":"2025072207313261700_ref13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3899\/jrheum.110755","article-title":"Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis","volume":"39","author":"Taniguchi","year":"2012","journal-title":"J Rheumatol"},{"key":"2025072207313261700_ref14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1053\/joca.1998.0147","article-title":"Production of cartilage oligomeric matrix protein (COMP) by cultured human dermal and synovial fibroblasts","volume":"6","author":"Dodge","year":"1998","journal-title":"Osteoarthr Cartil"},{"key":"2025072207313261700_ref15","doi-asserted-by":"publisher","first-page":"31166","DOI":"10.1074\/jbc.M705735200","article-title":"COMP acts as a catalyst in collagen fibrillogenesis","volume":"282","author":"Hal\u00e1sz","year":"2007","journal-title":"J Biol Chem"},{"key":"2025072207313261700_ref16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13073-017-0417-1","article-title":"A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis","volume":"9","author":"Taroni","year":"2017","journal-title":"Genome Med"},{"key":"2025072207313261700_ref17","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1136\/ard.2007.082099","article-title":"COMP: a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker","volume":"67","author":"Hesselstrand","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref18","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/rheumatology\/ker442","article-title":"Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease","volume":"51","author":"Hesselstrand","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"2025072207313261700_ref19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/BOR.0000000000000644","article-title":"T and B lymphocytes in fibrosis and systemic sclerosis","volume":"31","author":"Pillai","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2025072207313261700_ref20","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3389\/fimmu.2020.01142","article-title":"T cells in fibrosis and fibrotic diseases","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"2025072207313261700_ref21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13075-020-02383-w","article-title":"Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis","volume":"23","author":"Fox","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/rheumatology\/kead273","article-title":"Increased CD8+ tissue resident memory T cells, regulatory T cells and activated natural killer cells in systemic sclerosis lungs","volume":"63","author":"Padilla","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2025072207313261700_ref23","doi-asserted-by":"publisher","first-page":"867","DOI":"10.7150\/ijms.70984","article-title":"1,25OH-vitamin D3 and IL-17 inhibition modulate pro-fibrotic cytokines production in peripheral blood mononuclear cells of patients with systemic sclerosis","volume":"19","author":"Corrado","year":"2022","journal-title":"Int J Med Sci"},{"key":"2025072207313261700_ref24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jdermsci.2020.02.009","article-title":"The profiles of miRNAs and lncRNAs in peripheral blood neutrophils exosomes of diffuse cutaneous systemic sclerosis","volume":"98","author":"Li","year":"2020","journal-title":"J Dermatol Sci"},{"key":"2025072207313261700_ref25","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: a new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2025072207313261700_ref26","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"2025072207313261700_ref27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-018-1569-0","article-title":"Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression","volume":"20","author":"Bosello","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref28","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.3390\/cells9122627","article-title":"Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches","volume":"9","author":"Fetter","year":"2020","journal-title":"Cells"},{"key":"2025072207313261700_ref29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-07-294249","article-title":"Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells","volume":"117","author":"Iwata","year":"2011","journal-title":"Blood"},{"key":"2025072207313261700_ref30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","article-title":"Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity","volume":"55","author":"Matsushita","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2025072207313261700_ref31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025072207313261700_ref32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1084\/jem.185.3.461","article-title":"Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells","volume":"185","author":"Rinc\u00f3n","year":"1997","journal-title":"J Exp Med"},{"key":"2025072207313261700_ref33","doi-asserted-by":"publisher","first-page":"999008","DOI":"10.3389\/fimmu.2022.999008","article-title":"Dysregulated B cell function and disease pathogenesis in systemic sclerosis","volume":"13","author":"Beesley","year":"2023","journal-title":"Front Immunol"},{"key":"2025072207313261700_ref34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jdermsci.2019.12.007","article-title":"CD22 and CD72 contribute to the development of scleroderma in a murine model","volume":"97","author":"Zhao","year":"2020","journal-title":"J Dermatol Sci"},{"key":"2025072207313261700_ref35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10238-021-00745-5","article-title":"CD19 + CD21lo\/neg cells are increased in systemic sclerosis-associated interstitial lung disease","volume":"22","author":"Wilfong","journal-title":"Clin Exp Med"},{"key":"2025072207313261700_ref36","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI0215078","article-title":"CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse","volume":"109","author":"Saito","journal-title":"J Clin Invest"},{"key":"2025072207313261700_ref37","first-page":"397","article-title":"Cytokine-induced neutrophil-derived interleukin-8","volume":"141","author":"Strieter","year":"1992","journal-title":"Am J Pathol"},{"key":"2025072207313261700_ref38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/ijc.32151","article-title":"IL-10 derived from M2 macrophage promotes cancer stemness via JAK1\/STAT1\/NF-\u03baB\/Notch1 pathway in non-small cell lung cancer","volume":"145","author":"Yang","year":"2019","journal-title":"Int J Cancer"},{"key":"2025072207313261700_ref40","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.humimm.2021.03.009","article-title":"Peripheral cells from patients with systemic sclerosis disease co-expressing M1 and M2 monocyte\/macrophage surface markers: relation to the degree of skin involvement","volume":"82","author":"Mohamed","year":"2021","journal-title":"Hum Immunol"},{"key":"2025072207313261700_ref41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12931-018-0891-z","article-title":"A circulating cell population showing both M1 and M2 monocyte\/macrophage surface markers characterizes systemic sclerosis patients with lung involvement","volume":"19","author":"Trombetta","year":"2018","journal-title":"Respir Res"},{"key":"2025072207313261700_ref42","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1002\/art.41737","article-title":"Regulation of monocyte adhesion and type I interferon signaling by CD52 in patients with systemic sclerosis","volume":"73","author":"Rudnik","journal-title":"Arthritis Rheumatol"},{"key":"2025072207313261700_ref43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5345673","article-title":"Angiogenesis dysregulation in the pathogenesis of systemic sclerosis","volume":"2017","author":"Cantatore","year":"2017","journal-title":"Biomed Res Int"},{"key":"2025072207313261700_ref44","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.3389\/fimmu.2018.02045","article-title":"Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed?","volume":"9","author":"Bruni","year":"2018","journal-title":"Front Immunol"},{"key":"2025072207313261700_ref45","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1007\/s00018-008-8071-9","article-title":"TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions","volume":"65","author":"Irigoyen","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"2025072207313261700_ref46","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2006-07-036202","article-title":"The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration","volume":"110","author":"Grote","journal-title":"Blood"},{"key":"2025072207313261700_ref47","doi-asserted-by":"crossref","first-page":"107252","DOI":"10.1016\/j.vph.2023.107252","article-title":"Flow mediated dilation in systemic sclerosis: association with clinical findings, capillaroscopic patterns and endothelial circulating markers","volume":"154","author":"Corrado","year":"2023","journal-title":"Vasc Pharmacol"},{"key":"2025072207313261700_ref48","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.imlet.2017.10.007","article-title":"Agonistic antibodies in systemic sclerosis","volume":"195","author":"Moroncini","year":"2018","journal-title":"Immunol Lett"},{"key":"2025072207313261700_ref49","doi-asserted-by":"publisher","first-page":"606489","DOI":"10.3389\/fimmu.2020.606489","article-title":"The role of structure in the biology of interferon signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front Immunol"},{"key":"2025072207313261700_ref50","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3389\/fimmu.2021.595811","article-title":"Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and systemic sclerosis-associated interstitial lung disease","volume":"12","author":"Valenzi","year":"2021","journal-title":"Front Immunol"},{"key":"2025072207313261700_ref51","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref52","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1097\/BOR.0000000000000907","article-title":"Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit","volume":"34","author":"Kakkar","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"2025072207313261700_ref53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.autrev.2022.103185","article-title":"T cell abnormalities in systemic sclerosis","volume":"21","author":"Jin","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025072207313261700_ref54","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","article-title":"The immunopathogenesis of fibrosis in systemic sclerosis","volume":"195","author":"Brown","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"2025072207313261700_ref55","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1371\/annotation\/6b021f46-17bd-4ffe-a378-a1b8d24a1398","article-title":"Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?","volume":"3","author":"Fleming","year":"2008","journal-title":"PLoS One"},{"key":"2025072207313261700_ref56","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jid.2021.11.031","article-title":"Type I interferons in autoimmunity","volume":"142","author":"Fernandez-Ruiz","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025072207313261700_ref57","doi-asserted-by":"publisher","first-page":"R3","DOI":"10.1186\/ar3221","article-title":"Toll-like receptor 3 upregulation by type I interferon in healthy and scleroderma dermal fibroblasts","volume":"13","author":"Agarwal","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref58","doi-asserted-by":"publisher","first-page":"e436","DOI":"10.7417\/CT.2014.1789","article-title":"The Th1 chemokine IP-10 in systemic sclerosis","volume":"165","author":"Corrado","year":"2014","journal-title":"Clin Ter"},{"key":"2025072207313261700_ref59","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1002\/jcp.24337","article-title":"Interferon-\u03b3 promotes vascular remodeling in human microvascular endothelial cells by upregulating endothelin (ET)-1 and transforming growth factor (TGF) \u03b22","volume":"228","author":"Chrobak","year":"2013","journal-title":"J Cell Physiol"},{"key":"2025072207313261700_ref60","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1002\/art.34424","article-title":"Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells","volume":"64","author":"Wei","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2025072207313261700_ref61","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","article-title":"Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer","volume":"18","author":"Jones","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025072207313261700_ref62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/biomedicines10020318","article-title":"Targeting systemic sclerosis from pathogenic mechanisms to clinical manifestations: why IL-6?","volume":"10","author":"Cardoneanu","year":"2022","journal-title":"Biomedicines"},{"key":"2025072207313261700_ref63","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00403-019-01972-3","article-title":"The IL-4\/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targets","volume":"312","author":"Nguyen","year":"2020","journal-title":"Arch Dermatol Res"},{"key":"2025072207313261700_ref64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000163802","article-title":"In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease","volume":"61","author":"Koch","year":"1993","journal-title":"Pathobiology"},{"key":"2025072207313261700_ref65","first-page":"308","article-title":"Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis","volume":"25","author":"Hasegawa","year":"1998","journal-title":"J Rheumatol"},{"key":"2025072207313261700_ref66","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3899\/jrheum.120725","article-title":"Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis","volume":"40","author":"De Lauretis","year":"2013","journal-title":"J Rheumatol"},{"key":"2025072207313261700_ref67","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.cellsig.2008.01.006","article-title":"Targeting the TGF-\u03b2, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma","volume":"20","author":"Leask","year":"2008","journal-title":"Cell Signal"},{"key":"2025072207313261700_ref68","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025072207313261700_ref69","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1097\/00005344-199800001-00101","article-title":"Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts","volume":"31","author":"Xu","year":"1998","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025072207313261700_ref70","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/exd.13264","article-title":"Endothelial cell-derived endothelin-1 is involved in abnormal scar formation by dermal fibroblasts through RhoA\/Rho-kinase pathway","volume":"26","author":"Kiya","year":"2017","journal-title":"Exp Dermatol"},{"key":"2025072207313261700_ref71","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/ard.53.8.506","article-title":"Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis","volume":"53","author":"Kawaguchi","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref72","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13075-022-02787-w","article-title":"The role of endothelin and RAS\/ERK signaling in immunopathogenesis-related fibrosis in patients with systemic sclerosis: an updated review with therapeutic implications","volume":"24","author":"Rokni","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref73","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev-biochem-040320-103615","article-title":"The Wnt pathway: from signaling mechanisms to synthetic modulators","volume":"91","author":"Rim","year":"2022","journal-title":"Annu Rev Biochem"},{"key":"2025072207313261700_ref74","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/path.4481","article-title":"Sustained \u03b2-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes","volume":"235","author":"Hamburg-Shields","journal-title":"J Pathol"},{"key":"2025072207313261700_ref75","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/art.30312","article-title":"Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?","volume":"63","author":"Wei","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025072207313261700_ref76","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"key":"2025072207313261700_ref77","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/exd.14136","article-title":"Wnt antagonist DKK-1 levels in systemic sclerosis are lower in skin but not in blood and are regulated by microRNA33a-3p","volume":"30","author":"Henderson","year":"2021","journal-title":"Exp Dermatol"},{"key":"2025072207313261700_ref78","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1080\/15592294.2020.1827715","article-title":"microRNA27a-3p mediates reduction of the Wnt antagonist sFRP-1 in systemic sclerosis","volume":"16","author":"Henderson","year":"2021","journal-title":"Epigenetics"},{"key":"2025072207313261700_ref79","doi-asserted-by":"publisher","first-page":"e159884","DOI":"10.1172\/JCI159884","article-title":"Noncanonical WNT5A controls the activation of latent TGF-\u03b2 to drive fibroblast activation and tissue fibrosis","volume":"134","author":"Trinh-Minh","year":"2024","journal-title":"J Clin Invest"},{"key":"2025072207313261700_ref80","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10067-018-4298-5","article-title":"Dysregulation of the Wnt signaling pathway in South African patients with diffuse systemic sclerosis","volume":"38","author":"Frost","journal-title":"Clin Rheumatol"},{"key":"2025072207313261700_ref81","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2025072207313261700_ref82","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","article-title":"Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis","volume":"72","author":"Beyer","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref83","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest"},{"key":"2025072207313261700_ref84","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13075-018-1534-y","article-title":"Blockade of TGF-\u03b2\/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis","volume":"20","author":"Luong","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/978-3-642-54490-3_19","article-title":"5-Azacytidine\/5-Azacitidine","volume":"201","author":"M\u00fcller","year":"2014","journal-title":"Recent Results Cancer Res"},{"key":"2025072207313261700_ref86","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/annrheumdis-2012-203194","article-title":"The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis","volume":"73","author":"Dees","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref87","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"2025072207313261700_ref88","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1007\/s10067-023-06660-2","article-title":"Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease","volume":"42","author":"Junfei","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025072207313261700_ref89","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","article-title":"Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound","volume":"41","author":"Karalilova","journal-title":"Rheumatol Int"},{"key":"2025072207313261700_ref90","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025072207313261700_ref91","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40265-021-01604-z","article-title":"Anifrolumab: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"2025072207313261700_ref92","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1038\/jid.2015.188","article-title":"Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, Anifrolumab, in adult patients with systemic sclerosis","volume":"135","author":"Guo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2025072207313261700_ref93","doi-asserted-by":"publisher","first-page":"e002477","DOI":"10.1136\/rmdopen-2022-002477","article-title":"EUSTAR collaborators. Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort","author":"Kuster","year":"2022","journal-title":"RMD Open"},{"key":"2025072207313261700_ref94","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2025072207313261700_ref95","doi-asserted-by":"publisher","first-page":"4364","DOI":"10.1093\/rheumatology\/keac023","article-title":"Predictors of rituximab effect on modified Rodnan skin score in systemic sclerosis: a machine-learning analysis of the DesiReS\u2002trial","volume":"61","author":"Ebata","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"2025072207313261700_ref96","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025072207313261700_ref97","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.semarthrit.2020.08.004","article-title":"Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025072207313261700_ref98","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13075-016-1021-2","article-title":"Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study","volume":"18","author":"Schiopu","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025072207313261700_ref99","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1038\/s41467-023-41117-9","article-title":"Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis","volume":"14","author":"Ortega-Ferreira","year":"2023","journal-title":"Nat Commun"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1198\/680\/60956487\/qgae169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/101\/1198\/680\/60956487\/qgae169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T11:31:48Z","timestamp":1753183908000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/101\/1198\/680\/7916552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":99,"journal-issue":{"issue":"1198","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1093\/postmj\/qgae169","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2024,12,5]]}}}